Healthcare News

New preclinical data demonstrates PS-003 restores the key collagen protein missing in X-linked Alport Syndrome (XLAS) and is presented alongside findings from one of the largest genetic studies of...

FLINTLOCK Phase 2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in adults aged 18-65 years with Long COVID or...

Entrada Therapeutics announces that an independent DMC recommends initiation of Cohort 3 at the top dose of 18 mg/kg in the ELEVATE-44-201 study.

Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer

FDA’s Rare Disease Evidence Principles (RDEP) process aims to provide greater speed and predictability in the review of therapies for rare diseases with significant unmet medical need Acceptance...

Entrada Therapeutics announces positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45.

Arexera Therapeutics, Formerly Atalanta Therapeutics, Unveils New Corporate Identity and Advances Huntington's Disease Franchise

Elion has an exclusive global license to a novel inhaled polyene antifungal to prevent fungal infections in patients receiving immunosuppressive therapies.

New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors Zolucatetide directly inhibits...

Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually...